Treatment of patients with metastatic renal cell carcinoma undergoing hemodialysis: case report of two patients and short literature review

BMC Nephrology

Nicolas Tsavaris¹  Georgios Kechagias¹  John Syrios¹ 

[1]Oncology Unit, Department of Pathophysiology, Laikon General Hospital, Athens University School of Medicine, 75 M. Asias str, Athens, 115 27, Greece

关键词: Tyrosine kinase inhibitor;    Targeted agents;    Nephrectomy;    Hemodialysis;    Bilateral renal cell carcinoma;   

Others  :  1082954
DOI  :  10.1186/1471-2369-14-84

 received in 2013-01-16, accepted in 2013-04-09,  发布年份 2013

【 摘 要 】

Background

Renal cell carcinoma (RCC) may involve both kidneys. When bilateral nephrectomy is necessary renal replacement therapy is mandatory. Treating such patients with sequential therapy based on cytokines, antiangiogenic factors and mammalian target of rapamycin (mTOR) inhibitors is challenging.

Case presentation

The first case, a 50-year-old Caucasian female, underwent a radical right nephrectomy for RCC. Twelve years later she underwent a radical left nephrectomy along with total hysterectomy including bilateral salpingo-oophorectomy for RCC involving the right kidney and ovary. Hemodialysis was necessary because of bilateral nephrectomy. She relapsed with pulmonary metastases and enlarged mediastinal lymph nodes and received cytokine based therapy along with bevacizumab. Therapy was discontinued despite the partial response because of hemorrhagic gastritis. Therapy was switched to an antiangiogenic factor but the patient manifested a parietal brain hematoma and stopped therapy. Subsequently disease relapsed with malignant pleural effusion and pulmonary nodules and a mammalian target of rapamycin inhibitor was administered which was withdrawn only at patient’s deteriorating performance status. The patient died of the disease 13 years after the initial diagnosis of RCC.

The second case, a 51-year-old, Caucasian male, underwent a radical right nephrectomy for a chromophobe RCC. Six months later he underwent a radical left nephrectomy for RCC that proved to be a clear cell RCC. Due to bilateral nephrectomy hemodialysis was obligatory. Following disease recurrence at the anatomical bed of the right kidney therapy with antiangiogenic factor was administered which led to disease regression. However the patient experienced a left temporal-occipital brain hematoma. A radical excision of the recurrence which histologically proved to be a chromophobe RCC was not achieved and the patient received mTOR inhibitor which led to disease complete response. Nine years after the initial diagnosis of RCC he is disease free and leads an active life.

Conclusion

Patients with RCC are in significant risk to manifest bilateral disease. Renal insufficiency requiring hemodialysis poses therapeutic challenges. Clinicians must be aware of the antiangiogenic factors’ adverse effects, especially bleeding, that may manifest in higher frequency and more severe in this setting.

【 授权许可】

   
2013 Syrios et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Herrmann E, Bierer S, Wulfing C: Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 2010, 28(3):303-309.
• [2]Hofmann HS, Neef H, Krohe K, Andreev P, Silber RE: Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol 2005, 48(1):77-81. discussion 81–72
• [3]Athar U, Gentile TC: Treatment options for metastatic renal cell carcinoma: a review. Can J Urol 2008, 15(2):3954-3966.
• [4]Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, Lobel B, Guille F, Chopin DK, Mulders PF, Wood CG, Swanson DA, Figlin RA, Belldegrun AS, Pantuck AJ: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005, 23(12):2763-2771.
• [5]Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol 2004, 22(24):4991-5004.
• [6]Gnarra JR, Glenn GM, Latif F, Anglard P, Lerman MI, Zbar B, Linehan WM: Molecular genetic studies of sporadic and familial renal cell carcinoma. Urol Clin North Am 1993, 20(2):207-216.
• [7]Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO: Risk of bilateral renal cell cancer. J Clin Oncol 2009, 27(23):3737-3741.
• [8]Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345(23):1655-1659.
• [9]Russo P, Huang W: The medical and oncological rationale for partial nephrectomy for the treatment of T1 renal cortical tumors. Urol Clin North Am 2008, 35(4):635-643. vii
• [10]Procopio G, Verzoni E, Iacovelli R, Biasoni D, Testa I, Porcu L, De Braud F: Prognostic factors for survival in patients with metastatic renal cell carcinoma treated with targeted therapies. Br J Cancer 2012, 107(8):1227-1232.
• [11]Janus N, Thariat J, Boulanger H, Deray G, Launay-Vacher V: Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. Ann Oncol 2010, 21(7):1395-1403.
• [12]Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, Morere JF, Beuzeboc P, Deray G: Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer 2007, 110(6):1376-1384.
• [13]Izzedine H, Etienne-Grimaldi MC, Renee N, Vignot S, Milano G: Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009, 20(1):190-192.
• [14]Lunardi G, Vannozzi MO, Armirotti A, Nicodemo M, Venturini M, Cavallini L: Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol 2008, 26(34):5652-5653. author reply 5653–5654
• [15]Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, Lewis LD, Fakih MG, Edelman MJ, Millard F, Frank RC, Hohl RJ, Ratain MJ: Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009, 27(11):1800-1805.
• [16]Thiery-Vuillemin A, Curtit E, Maurina T, Montange D, Succi C, Nguyen T, Kim S, Montcuquet P, Pivot X, Royer B: Hemodialysis does not affect everolimus pharmacokinetics: two cases of patients with metastatic renal cell cancer. Ann Oncol 2012, 23(11):2992-2993.
• [17]Henriksson C, Geterud K, Aldenborg F, Zachrisson BF, Pettersson S: Bilateral asynchronous renal cell carcinoma. Computed tomography of the contralateral kidney 10–43 years after nephrectomy. Eur Urol 1992, 22(3):209-212.
• [18]Rabbani F, Herr HW, Almahmeed T, Russo P: Temporal change in risk of metachronous contralateral renal cell carcinoma: influence of tumor characteristics and demographic factors. J Clin Oncol 2002, 20(9):2370-2375.
• [19]Klatte T, Patard JJ, Wunderlich H, Goel RH, Lam JS, Junker K, Schubert J, Bohm M, Allhoff EP, Kabbinavar FF, Crepel M, Cindolo L, De La Taille A, Tostain J, Mejean A, Soulie M, Bellec L, Bernhard JC, Ferriere JM, Pfister C, Albouy B, Colombel M, Zisman A, Belldegrun AS, Pantuck AJ: Metachronous bilateral renal cell carcinoma: risk assessment, prognosis and relevance of the primary-free interval. J Urol 2007, 177(6):2081-2086. discussion 2086–2087
• [20]Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011, 60(4):615-621.
• [21]Hafez KS, Fergany AF, Novick AC: Nephron sparing surgery for localized renal cell carcinoma: impact of tumor size on patient survival, tumor recurrence and TNM staging. J Urol 1999, 162(6):1930-1933.
• [22]Lobbedez T, Hurault de Ligny B, Galateau F, Potier J, Elie H, Ryckelynck JP: Synchronous bilateral renal cell carcinoma. Renal transplantation after nephrectomy. Presse Med 1997, 26(2):66-69.
• [23]Rowland M, Tozer T (Eds): Dialysis in Clinical Pharmacokinetics. Concepts and Applications. 3rd edition. Philadelphia: Lippincott Williams & Wilkins; 1995.
• [24]Bellmunt J: Future developments in renal cell carcinoma. Ann Oncol 2009, 20(Suppl 1):i13-i17.
• [25]Staehler M, Haseke N, Zilinberg E, Stadler T, Karl A, Siebels M, Durr HR, Siegert S, Jauch KW, Bruns CJ, Stief CG: Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. Urol Oncol 2010, 28(2):139-144.
• [26]Nemoto K, Miura T, Shioji G, Tsuboi N: Complete remission of renal cell carcinoma with lung metastases in two hemodialysis patients after low-dose interferon therapy. Hemodial Int 2011, 15(2):288-292.
• [27]Hanazawa K, Tanaka M, Watanabe R, Fujime M: Interferon therapy for renal cell carcinoma in hemodialysis patients: report of two patients. Int J Urol 2000, 7(5):189-192.
• [28]Garnier-Viougeat N, Rixe O, Paintaud G, Ternant D, Degenne D, Mouawad R, Deray G, Izzedine H: Pharmacokinetics of bevacizumab in haemodialysis. Nephrol Dial Transplant 2007, 22(3):975.
• [29]Horimatsu T, Miyamoto S, Morita S, Mashimo Y, Ezoe Y, Muto M, Chiba T: Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy. Cancer Chemother Pharmacol 2011, 68(1):263-266.
• [30]Kuwabara H, Baba H, Wakabayashi M, Nakamura H, Sanada T, Baba H, Nakajima K, Goseki N: mFOLFOX6 and FOLFIRI/bevacizumab treatment in a patient on hemodialysis with metastatic colon cancer. Gan To Kagaku Ryoho 2011, 38(12):2250-2252.
• [31]Josephs D, Hutson TE, Cowey CL, Pickering LM, Larkin JM, Gore ME, Van Hemelrijck M, McDermott DF, Powles T, Chowdhury P, Karapetis C, Harper PG, Choueiri TK, Chowdhury S: Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. BJU Int 2011, 108(8):1279-1283.
• [32]Masini C, Sabbatini R, Porta C, Procopio G, Di Lorenzo G, Onofri A, Buti S, Iacovelli R, Invernizzi R, Moscetti L, Aste MG, Pagano M, Grosso F, Lucia Manenti A, Ortega C, Cosmai L, Del Giovane C, Conte PF: Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int 2012, 110(5):692-698.